Aidoc, a leading provider of AI for medical imaging, and ScreenPoint Medical, a leader of deep learning AI for 2D and 3D mammography have announced a collaboration which will incorporate ScreenPoint’s capabilities into Aidoc’s platform. Breast imaging specialists will now be able to benefit from one point of access to AI within the existing physician workflow, providing for early detection and diagnosis of…
Delphinus has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its SoftVue 3D Whole Breast Ultrasound Tomography System for use as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue. Clinical evidence has demonstrated that SoftVue enhances dense breast screening and identifies up to 20% more cancers with greater accuracy…
Brilliantly and Mammogen, two female-led women’s health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, have announce a new partnership with the goal to improve quality of care for the breast cancer community, both inside and outside of the physician’s office. The collaboration, which will equip breast cancer previvors and survivors with the tools they…
Bloomer Tech is a venture-backed startup focused on solutions for cardiovascular disease and stroke in women, ushering the new age of equitable personalized diagnostics. Its founder, Alicia Chong Rodriguez, recently spoke at TED sharing her company’s story and mission of transforming everyday bras into smart medical devices that gather often-overlooked data on heart disease in women, a frequently misdiagnosed and under-researched killer.…
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program has reported that approximately 12.9% of women will get diagnosed with cancer in their lifetime. Although Black women get breast cancer at a slightly lower incidence rate (3%) than white women, Black women are 42% more likely to face mortality. This Fall, The Chrysalis Initiative (TCI) will launch BC Navi, a…
Roche has decided to withdraw its immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States. The drug received accelerated approval in 2019 to treat inoperable, locally advanced or metastatic triple-negative breast cancer (mTNBC) in people whose tumors express PD-L1, a protein that may help the cancer avoid detection by the immune system. But it failed last year…
FUJIFILM, a provider of diagnostic imaging and medical informatics solutions, has announced that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now offers ScreenPoint Medical’s new, FDA cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States. ScreenPoint Medical’s AI solution, coupled with the ASPIRE Cristalle mammography system, displays breast screening findings at a doctor’s reading workstation or PACS…
Volpara Health has announced Jill Spear as the new Executive Vice President of Sales and Marketing who will drive continued growth for Volpara’s integrated software platform that assists in the delivery of personalized breast care. In this role, Spear will expand sales of the company’s breast cancer risk assessment, detection, imaging analytics and patient tracking software in North America. Earlier this year, Volpara acquired CRA Health,…
